Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced findings from an independent study demonstrating the potential for Bryostatin-1 as a treatment strategy for amyotrophic lateral sclerosis ("ALS"), also known as Lou Gehrig's Disease.
An open access article about the study was published in a special issue of the International Journal of Molecular Sciences titled "Neurodegenerative Disease: From Molecular Basis to Therapy." Under the leadership of Professor Sebastiano Cavallaro, an internationally recognized expert in the genetics of ALS, the study was conducted by scientists at the Institute for Biomedical Research and Innovation and the National Research Council of Italy, in collaboration with the University of Catania. Dr. Cavallaro has served for over 20 years as Research Director for the Institute for Biomedical Research and Innovation.
The new article demonstrates that the gene encoding for the enzyme protein kinase C epsilon ("PKCε"), the primary initial target of Bryostatin-1, showed an expression level that was significantly reduced (p<.001, 2-tailed) in the motor cortex samples taken from a genetically identified population of ALS patients when compared to control patients. Furthermore, in pre-clinical murine motor neurons genetically engineered to model the genetic signature of these ALS patients, there was a significant (p<.001, 2-tailed) reduction in the level of activated PKCε. Bryostatin-1 treatment of these ALS motor neurons significantly reversed the PKCε deficits.
Dr. Sebastiano Cavallaro stated, "Taken together, our findings suggest that PKCε alteration could play a role in ALS pathophysiology, and that PKCε agonism by Bryostatin-1 may represent a potential neuroprotective strategy against motor neuronal degeneration — at least in a specific subgroup of sporadic ALS patients."
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.